Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Publication year range
1.
Antiviral Res ; 134: 130-143, 2016 10.
Article in English | MEDLINE | ID: mdl-27515131

ABSTRACT

HCMV is a member of the family Herpesviridae and represents a worldwide distributed pathogen with seropositivity rates in the adult population ranging between 40% and 90%. Notably, HCMV infection is a serious, sometimes life-threatening medical problem for newborns and immunosuppressed individuals, including transplant recipients and patients under antitumoral chemotherapy. Current standard therapy with valganciclovir has the disadvantage of inducing drug-resistant virus mutants and toxicity-related side effects. Our analysis stresses the earlier finding that kinase inhibitors of the quinazoline class exert an antiviral response by targeting the viral protein kinase pUL97 without inducing resistance. Therefore, quinazolines have been used as a core structure to gain insight in the mode of inhibitor-kinase interaction. Here, we demonstrate that (i) the novel quinazolines Vi7392 and Vi7453 are highly active against HCMV laboratory and clinically relevant strains including maribavir- and ganciclovir-resistant variants, (ii) antiviral activity is not cell-type specific and was also detected in a placental explant tissue model using a genetically intact HCMV strain (iii) the viral kinase pUL97 represents a target of the anticytomegaloviral activity of these compounds, (iv) induction of pUL97-conferring drug resistance was not detectable under single-step selection, thus differed from the induction of ganciclovir resistance, and (v) pUL97 drug docking simulations enabled detailed insights into specific drug-target binding properties providing a promising basis for the design of optimized kinase inhibitors. These novel findings may open new prospects for the future medical use of quinazoline drug candidates and the use of drug-target dynamic simulations for rational design of antivirals.


Subject(s)
Cytomegalovirus/drug effects , Drug Design , Protein Kinase Inhibitors/pharmacology , Quinazolines/pharmacology , Antiviral Agents/chemistry , Antiviral Agents/isolation & purification , Antiviral Agents/pharmacology , Cells, Cultured , Cytomegalovirus/chemistry , Cytomegalovirus/enzymology , Drug Resistance, Viral , Female , Fibroblasts/virology , Humans , Models, Molecular , Molecular Docking Simulation , Placenta/cytology , Pregnancy , Protein Kinase Inhibitors/chemistry , Quinazolines/chemistry , Quinazolines/classification , Viral Proteins/chemistry , Viral Proteins/drug effects , Virus Replication/drug effects
2.
Pharmazie ; 47(7): 525-8, 1992 Jul.
Article in English | MEDLINE | ID: mdl-1518898

ABSTRACT

Convulsions induced by acute administration of isoniazid (1), theophylline (2) as well as combinations of 1 and 2 were evaluated in male albino mice and male Wistar rats. The effect of pyridoxine (3) on these seizures was tested. Serum and brain levels of 1 after coadministration with 2 and caffeine (4) were assessed. The relevance of the observed pharmacokinetic phenomena in serum is questionable for the CNS processes because animals convulsed late (starting 90 min) and no significant changes of brain levels of 1 were observed. In conclusion, interactions of 1 and 2 may not occur through common mechanisms and exist only if the dose of 1 is toxic suggesting toxicological rather than therapeutic relevance.


Subject(s)
Convulsants/pharmacology , Isoniazid/pharmacology , Pyridoxine/pharmacology , Theophylline/pharmacology , Animals , Brain/metabolism , Caffeine/metabolism , Drug Interactions , Isoniazid/pharmacokinetics , Male , Mice , Pyridoxine/pharmacokinetics , Rats , Rats, Inbred Strains , Theophylline/pharmacokinetics
SELECTION OF CITATIONS
SEARCH DETAIL
...